Department of Cardiovascular Surgery, Bartın State Hospital, Bartın, Turkey.
Department of Cardiovascular Surgery, Karadeniz Eregli State Hospital, Zonguldak, Turkey.
Ann Vasc Surg. 2022 Nov;87:502-507. doi: 10.1016/j.avsg.2022.05.033. Epub 2022 Jun 26.
The objective of this study was to describe the contribution and advantage of balloon-dilatation of iliac and femoral veins following pharmacomechanical catheter-directed thrombolysis (PCDT) on the development of post-thrombotic syndrome (PTS).
From October 2018 and January 2022, 85 patients with acute total occlusion of the iliac and femoral veins were treated with PCDT. The cohort was divided into 2 groups depending on the utilization of concomitant balloon dilatation of iliac and femoral veins (Group 1, n = 34, 40.0%) or not (Group 2, n = 51, 60.0%) during the PCDT. All patients underwent duplex ultrasound scanning for evaluating the patency of iliac veins and recanalization rates at 3, 6, and 12 months postoperatively. The Villalta score was used to score the severity of PTS at 12 months postoperatively.
Patients who underwent balloon-assisted PCDT (group 1) exhibited significantly higher primary patency rates in common iliac vein (CIV) (recanalization 84.3 ± 14.6%, P = 0.003), external iliac vein (EIV) (recanalization 82.8 ± 17.2, P = 0.003) and common femoral vein (CFV) (recanalization 88.1 ± 12.1%, P = 0.038) compared with the group 2 at the end of 12 months follow-up. Only 2 patients underwent venous stenting in follow-up due to severe venous claudication, however, 13 patients were required iliac vein stenting due to severe PTS proved with a high Villalta score at 12-month follow-up. The d-dimer level at 1-year follow-up had also significantly lower in Group 1 due to higher rates of patency and lower thrombosis burden. The most common bleeding events were hematuria (n = 4) or oozing in the puncture site (n = 4).
This study showed that balloon-assisted PCDT reduces the risk of PTS, is more successful in common iliac vein recanalization, reduces the need for the venous stent, and even lowers the D-dimer levels of the patients compared to routine PCDT alone.
本研究旨在描述在药物机械导管溶栓(PCDT)后行髂股静脉球囊扩张术对血栓后综合征(PTS)发展的贡献和优势。
2018 年 10 月至 2022 年 1 月,85 例髂股静脉急性完全闭塞患者接受了 PCDT 治疗。根据是否在 PCDT 过程中同时行髂股静脉球囊扩张术(1 组,n=34,40.0%)将患者分为两组。所有患者均接受双功能超声检查,以评估术后 3、6 和 12 个月髂静脉通畅率和再通率。术后 12 个月采用 Villalta 评分评估 PTS 严重程度。
行球囊辅助 PCDT(1 组)的患者髂总静脉(CIV)(再通率 84.3%±14.6%,P=0.003)、髂外静脉(EIV)(再通率 82.8%±17.2%,P=0.003)和股总静脉(CFV)(再通率 88.1%±12.1%,P=0.038)的通畅率在 12 个月的随访中明显高于 2 组。仅 2 例因严重静脉跛行在随访中接受静脉支架置入术,而 13 例因严重 PTS (高 Villalta 评分)在 12 个月的随访中需要髂静脉支架置入术。由于通畅率较高和血栓负荷较低,1 组患者的 D-二聚体水平在 1 年随访时也明显较低。最常见的出血事件是血尿(n=4)或穿刺部位渗血(n=4)。
与单纯常规 PCDT 相比,球囊辅助 PCDT 降低了 PTS 风险,髂总静脉再通更成功,降低了静脉支架的需求,甚至降低了患者的 D-二聚体水平。